Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

M. Fradkin



Author of

  • +

    OA14 - Nurses in Care for Lung Cancer and in Research (ID 398)

    • Event: WCLC 2016
    • Type: Oral Session
    • Track: Nurses
    • Presentations: 1
    • +

      OA14.02 - Nursing and Allied Healthcare Practitioner Driven Initiative to Develop an Integrated Educational and Assessment Program for Immunotherapy (ID 5716)

      16:10 - 16:20  |  Author(s): M. Fradkin

      • Abstract
      • Presentation
      • Slides

      Background:
      Immunotherapy is rapidly becoming recognized as the fourth pillar of treatment for lung cancer. As an academic center of excellence, our staff have developed expertise with immune-oncology (I-O) agents though clinical trials. Currently two agents (Nivolumab and Pembrolizumab) have been FDA-approved for the treatment of lung cancer. Variability existed in patient assessment, patient education and staff education regarding how to identify and manage immune-related adverse events (IrAEs).

      Methods:
      Initial evaluation consisted of an online staff survey and interviews to assess the educational materials available for instruction of both patients and staff. A review of existing educational materials was conducted to determine the breadth of information available as well as knowledge gaps. The evaluation revealed a lack of standardization, with inconsistency in the educational messages being delivered. A focused working group including CNS, APRNs, Pharmacists and RNs from the academic hub and broader community care center network was convened with the goal of developing educational platforms for nursing staff as well as patients. Bringing stakeholders together was felt to be important to increase buy-in across the spectrum of care locations, as well as to ensure that the program was effective and appropriate for all sites. Program components included the following: -Education for staff to better identify and manage IrAEs -Development of an electronic nursing flow-sheet to standardize patient assessment and document IrAEs in the lung cancer population. -Automatic notification through the EMR to alert staff in non-oncology settings regarding I-O patients. -Development of a forum for patient education to better understand I-O therapy and how to identify and manage IrAEs. - Development of lung cancer specific telephone triage guidelines

      Results:
      The outcomes of implementing the I-O program include increased patient participation in educational forums and improved patient satisfaction metrics. Incorporation of the I-O assessment flow-sheet and telephone triage guidelines will improve staff competency, as well as standardize documentation and monitoring of IrAEs. These metrics will allow for more accurate tracking of IrAes throughout the course of treatment.

      Conclusion:
      The I-O Integrated Education and Assessment Program standardizes practice across all oncology care delivery sites within our network. This program allows patients to receive the highest level of care at convenient regional locations closer to home, with the goal of maintaining patient safety while maximizing the benefit they may receive from I-O therapies. An integrated

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.